Om du vill rapportera en biverkning gällande en av Lillys produkter, kontakta oss via e-post på DK_PHv@lilly.com eller på telefon +45 4526 6040. Har du ytterligare medicinska frågor gällande en av Lillys produkter, kontakta oss via länken ovan.
Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska
The RELAY trial was a phase 3, global, multicenter, randomized, double-blind, placebo-controlled trial in patients (N=449) with previously untreated EGFR mutation-positive, metastatic NSCLC. All patients had an EGFR mutation of exon 19 deletion or exon 21 L858R and an ECOG PS of 0 or 1. Patients were randomly assigned in a 1:1 ratio (stratified by sex, region, EGFR status, and EGFR testing method) to receive treatment with erlotinib (150 mg/day) plus ramucirumab (10 mg/kg every 2 weeks; n=224) or placebo (10 mg/kg every 2 weeks; n=225) until disease progression or unacceptable toxicity.1
Treatment Duration
The median duration of ramucirumab treatment was longer than that of placebo and the median duration of erlotinib treatment was longer in the ramucirumab plus erlotinib arm than in the placebo plus erlotinib arm.2 Additional details on treatment duration are summarized in Table 1.
Table 1. Duration of Treatmenta2
|
|
Ramucirumab
+ Erlotinib |
Erlotinib
+ Placebo |
|
Ramucirumab or Placebob |
||
|
Median duration of therapy, months (range) |
11.04 (0.46-33.81) |
9.66 (0.46-35.42) |
|
Median infusions received per patient (range) |
21.00 (1.00-69.00) |
19.00 (1.00-74.00) |
|
Erlotinibb |
||
|
Median duration of therapy, months (range) |
14.13 (0.03-33.84) |
11.20 (0.36-35.45) |
|
Median weeks on treatment per patient (range)c |
60.00 (0-138.00) |
47.00 (1.00-152.00) |
a Data cutoff date: 23 January 2019.
b Number of patients who received at least one dose of study drug ramucirumab or placebo or erlotinib, either partial or complete.
c Patient is considered to have received a week of therapy after receiving at least 7 doses of erlotinib, either partial or complete.
1. Nakagawa K, Garon EB, Seto T, et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(12):1655-1669. https://doi.org/10.1016/S1470-2045(19)30634-5
2. Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Glossary
ECOG = Eastern Cooperative Oncology Group
EGFR = epidermal growth factor receptor
NSCLC = non-small cell lung cancer
PS = performance status
Datum fӧr senaste ӧversyn 2019 M07 24